Antibodies specific for CLL-1

A method of treating a myeloproliferative disorder in an individual, wherein the myeloproliferative disorder is acute myeloid leukemia (AML), the method comprising

• administering to the individual an antibody that binds to human C-type lectin like molecule 1 (CLL-1), wherein the antibody is selected from the group consisting of:
• an antibody comprising heavy chain complementarity determining regions (CDRs) of SEQ ID NOs:51, 59, and 67, and light chain CDRs of SEQ ID NOs:75, 83, and 91;
• an antibody comprising heavy chain CDRs of SEQ ID NOs:52, 60, and 68, and light chain CDRs of SEQ ID NOs:76, 84, and 92;
• and
• an antibody comprising heavy chain CDRs of SEQ ID NOs:53, 61, and 69 and light chain CDRs of SEQ ID NOs:77, 85, and 93,
• thereby treating the myeloproliferative disorder in the individual.